Dogwood Therapeutics to report third quarter 2024 results and corporate update on November 7

Dogwood Therapeutics, formerly Virios Therapeutics, will release its third quarter 2024 financial results on November 7, 2024. A conference call will follow at 8:30 a.m. ET to discuss the results and provide updates. The company focuses on developing treatments for pain and fatigue-related disorders. Its research includes a non-opioid analgesic program and an antiviral program targeting conditions linked to dormant herpes viruses. Top-line data from an ongoing Phase 2 study of its antiviral treatment for Long-COVID is expected in mid-November 2024. The company is also preparing to advance another treatment for fibromyalgia into Phase 3 development.